The latest from Cogstate, leaders in optimizing the measurement of cognition

AMPAR Potentiators May Have Role In The Treatment Of The Cognitive Symptoms Associated With Schizophrenia

March 15, 2017

Treating schizophrenia involves not only addressing the primary positive and negative symptoms but also the frequent cognitive dysfunction that accompanies the disorder, known as cognitive impairment associated with schizophrenia (CIAS). These deficits in attention, working memory and executive function have a detrimental impact on a patient’s quality of life and their functional capacity to manage […]

Study Finds Brexpiprazole To Be An Effective Alternative To Aripiprazole

November 8, 2016

Despite the number of available antipsychotics, schizophrenia is still a complicated brain disorder to treat, in part due to the different side effects of various treatment regimens between patients. Brexpiprazole, a serotonin-dopamine activity modulator approved by the FDA for schizophrenia in 2015, was developed by Otsuka as a successor to aripiprazole, whose U.S. patent expired […]

Study Finds Use of Nicotinic Alpha-7 Agonist Improves Cognitive Function In Parkinson’s Patients

March 24, 2016

For patients diagnosed with Parkinson’s disease (PD), the need to balance effective treatments with their unpleasant side effects is an ongoing battle. Long considered the gold standard for treating early symptoms of PD, levodopa (L-DOPA) is able to cross the blood-brain barrier to produce dopamine in the brain which helps manage the symptoms of motor […]

Schizophrenia Compound Advances to Phase III After Positive Results for Cognitive Function

August 15, 2015

Cogstate was Primary Endpoint in the Multinational Phase II Study Battling schizophrenia is typically a two-prong attack, one to treat the “positive” symptoms, such as hallucinations, delusions and paranoia and one to help with the “negative” symptoms that affect everyday functioning including cognitive impairment. While treatments exist to manage the positive symptoms, there is an […]

Cognigram Detects Cognitive Impairment In Schizophrenia Patients

April 10, 2014

Patients diagnosed with schizophrenia have to battle not only the more well-known emotional symptoms of the mental disorder but often suffer from cognitive impairment including deficits in reaction time, attention, working memory and learning.  Even those who are already being treated with antipsychotic medication also need to have pharmacologic or behavioral therapies to control the […]

Groton Maze Learning Test Found To Be Accurate Indicator For Executive Function In Schizophrenia Patients

February 24, 2014

One of the brain’s most important roles is coordinating our daily life through an ongoing series of activities including decision making, planning, reasoning and problem solving. This collection of tasks, known as executive function, is called on when a new situation requires a novel response. It is often this set of cognitive abilities that breaks […]

Controlling Anxiety Symptoms May Slow Cognitive Decline

February 21, 2014

While Alzheimer’s disease is best known as a memory degradation disease, there are often additional symptoms that result from abnormally high levels of beta amyloid, the plaque in the brain that often leads to the disease. Behavioral issues like anxiety, irritability and even depression can affect a patient’s quality of life, sometimes even before a […]

Cogstate Testing Shows Effective Treatment For Schizophrenia Symptoms

September 22, 2013

For patients dealing with the everyday struggles of schizophrenia, any improvement in their cognitive functioning is welcome news.  Since there is no cure for the disorder, care providers have focused on relieving these symptoms with proven medications.  Now, a team of neuroscientists, including Dr. Paul Maruff, Chief Science Officer at Cogstate, have reported that Lurasidone, […]